13价肺炎球菌结合疫苗对中国上海5岁以下儿童全因肺炎的有效性:一项观察性研究
该观察性研究描述了2017至2020年上海5岁以下儿童PCV13接种趋势与肺炎发病率,并通过倾向评分匹配比较接种与未接种儿童,估算PCV13对社区获得性肺炎的有效性。结果显示至少接种1剂后对全因肺炎就诊的疫苗有效性为19%(95%CI:3至32),对住院肺炎的有效性为30%(95%CI:5%至49%),高于门诊肺炎的19%(95%CI:4%至32%)。结论认为PCV13接种大幅降低了0-5岁儿童全因肺炎发病率。
要点
- 至少接种1剂PCV13后对全因肺炎就诊的疫苗有效性为19%(95%CI:3至32)。
- 对住院肺炎的保护性有效性为30%(95%CI:5%至49%),高于门诊肺炎的19%(95%CI:4%至32%)。
- 接种3剂及以上PCV13的儿童占所有接种儿童的85.7%。
核心结论
- 0-5岁儿童接种PCV13大幅降低了全因肺炎发病率。
- 直接为5岁以下儿童接种是应对门诊肺炎和住院肺炎的有效策略。
研究设计与样本
- 观察性研究,采用逻辑回归计算倾向评分,按1:1频率匹配未接种与接种儿童,使用最近邻匹配算法和精确匹配,并为两个队列创建不同的匹配分析集。
- 采用Kaplan-Meier分析测量两组全因肺炎累积发病率,以log-rank检验评估两条累积发病率曲线的差异。
- 采用Cox比例风险回归比较两组全因肺炎差异的调整后风险比(HR)。
- 研究对象为2017至2020年中国上海5岁以下儿童。
主要发现
- 接种3剂及以上PCV13的儿童占所有接种儿童的85.7%。
- 上海松江区肺炎发病率自2017年起迅速下降,同期PCV13接种呈总体上升趋势。
- 至少接种1剂PCV13的儿童中,对全因肺炎就诊的估算疫苗有效性为19%(95%CI:3至32)。
- PCV13对住院肺炎的保护性有效性为30%(95%CI:5%至49%),高于门诊肺炎的19%(95%CI:4%至32%)。
临床怎么用
- 作者认为直接为5岁以下儿童接种是应对门诊肺炎和住院肺炎的有效策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Streptococcus pneumoniae (Spn) is a common respiratory pathogen and the main cause of bacterial pneumonia, meningitis, and bacteremia, acute otitis media. Imported 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in China and introduced in Shanghai in 2017. We aim to describe PCV13 vaccination trends and pneumonia incidence of children under 5 from 2017 to 2020, then estimate the effectiveness of PCV13 against community-acquired pneumonia (CAP) in children under 5 in Shanghai, China. METHODS: By calculating propensity scores with logistic regression, a comparison group was formed by frequency matching one unvaccinated child to one vaccinated child. For matching, we used the nearest-neighbor matching algorithm and exact matching, and then created distinct matched analysis sets for two cohorts. A Kaplan-Meier analysis was conducted to measure the cumulative incidence of all-cause pneumonia in both groups and used the log-rank test to assess the differences between the two cumulative incidence curves. Cox proportional hazards regression was used to compare the adjusted hazard ratios (HR) of differences in all-cause pneumonia between the two groups. RESULTS: Children received three or more doses PCV13 accounted for 85.7% of all vaccinated children. The incidence of pneumonia in Shanghai's Songjiang district decreased rapidly from 2017, when PCV13 vaccination presented an overall increasing trend. The estimated vaccine effectiveness against visits for all-cause pneumonia was 19% (95% CI: 3 to 32) after the first dose in children vaccinated with at least one dose of PCV13. The protective effectiveness of PCV13 was found to be higher for hospitalized pneumonia (30%, 95% CI: 5% to 49%) than for outpatient pneumonia (19%, 95% CI: 4% to 32%). CONCLUSIONS: PCV13 vaccination among children aged 0-5 years substantially reduced the incidence of all-cause pneumonia. Direct immunization of children under 5 years is an effective strategy to combat outpatient pneumonia, and hospitalized pneumonia.
引用
- Tian J, Zheng B, Yang L, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study. Vaccine. 2023. PMID: 37620204. doi:10.1016/j.vaccine.2023.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。